Recent studies have shown that overexpression of COX-2 and PGE2 is a characteristic of many human cancers [48-50] and selective COX-2 inhibitors have shown significant effects in reducing the incidence and progression of tumors and metastasis in animal models of mammary cancer [51-53]. This evidence concerns the gene PTGS2 and cancer.